Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...